Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2026)

Arcus Biosciences' Long-Term Investments history runs 10 years deep, the most recent figure standing at $54.0 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 575.0% year-over-year to $54.0 million in Q1 2026; TTM through Mar 2026 was $54.0 million, a 575.0% increase from a year earlier, with the FY2025 full-year figure at $29.0 million, up 107.14% from the prior year.
• Long-Term Investments rose to $54.0 million in Q1 2026 per RCUS's latest filing, from $29.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $151.0 million in Q3 2023 and bottomed at $2.0 million in Q3 2024.
• The 5-year median for Long-Term Investments is $80.0 million (2023), against an average of $70.6 million.
• Across the five-year window, Long-Term Investments tumbled 98.68% in 2024 and soared 575.0% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $129.0 million in 2022, then decreased by 17.05% to $107.0 million in 2023, then slumped by 86.92% to $14.0 million in 2024, then surged by 107.14% to $29.0 million in 2025, then surged by 86.21% to $54.0 million in 2026.
• Per Business Quant, the three latest RCUS Long-Term Investments figures stand at $54.0 million (Q1 2026), $29.0 million (Q4 2025), and $10.0 million (Q3 2025).